Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer

Koichi Takayama, Kenichi Ogata, Yoichi Nakanishi, Jun Yatsunami, Masayuki Kawasaki, Nobuyuki Hara

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

PURPOSE: The bcl-2 gene belongs to a new category of oncogene that inhibits programmed cell death (apoptosis). No data are available on the frequency or clinical importance of its expression in patients with small cell lung cancer (SCLC), although its expression is reported in SCLC cell lines. We investigated the correlation between bcl-2 expression and prognosis, including response to chemotherapy, in SCLC patients and report our findings here. MATERIALS AND METHODS: Tumor specimens biopsied bronchoscopically in 38 SCLC patients were used for immunohistochemical study. Bcl-2 oncoprotein was detected by obtaining an immunostain using a specific monoclonal antibody, DAKO-bcl-2, 124. All patients received more than two courses of chemotherapy with 3- to 4-week intervals. RESULTS: We detected bcl-2 expression in 21 of the 38 SCLC patients (55%). In 17 patients with bcl-2-negative tumors, the objective response to chemotherapy was 76% with 12% complete response and in 21 patients with bcl-2-positive tumors it was 62% with 8% complete response. The difference in response rate was not significant. In patients with bcl-2-positive tumors, survival time tended to be shorter than in those with bcl-2-negative tumors. There was no significant correlation between bcl-2 expression and clinical factors (gender, age, smoking, performance score, staging). CONCLUSIONS: In 21 of the 38 SCLC patients bcl-2 oncoprotein was abnormally expressed and its expression may be associated with shorter survival times and poor response to chemotherapy.

Original languageEnglish
Pages (from-to)212-216
Number of pages5
JournalCancer Journal from Scientific American
Volume2
Issue number4
Publication statusPublished - Dec 1 1996

Fingerprint

Small Cell Lung Carcinoma
Survival
Drug Therapy
Oncogene Proteins
Neoplasms
bcl-2 Genes
Age Factors
Oncogenes
Cell Death
Smoking
Monoclonal Antibodies
Apoptosis
Cell Line

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Takayama, K., Ogata, K., Nakanishi, Y., Yatsunami, J., Kawasaki, M., & Hara, N. (1996). Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer. Cancer Journal from Scientific American, 2(4), 212-216.

Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer. / Takayama, Koichi; Ogata, Kenichi; Nakanishi, Yoichi; Yatsunami, Jun; Kawasaki, Masayuki; Hara, Nobuyuki.

In: Cancer Journal from Scientific American, Vol. 2, No. 4, 01.12.1996, p. 212-216.

Research output: Contribution to journalArticle

Takayama, K, Ogata, K, Nakanishi, Y, Yatsunami, J, Kawasaki, M & Hara, N 1996, 'Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer', Cancer Journal from Scientific American, vol. 2, no. 4, pp. 212-216.
Takayama K, Ogata K, Nakanishi Y, Yatsunami J, Kawasaki M, Hara N. Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer. Cancer Journal from Scientific American. 1996 Dec 1;2(4):212-216.
Takayama, Koichi ; Ogata, Kenichi ; Nakanishi, Yoichi ; Yatsunami, Jun ; Kawasaki, Masayuki ; Hara, Nobuyuki. / Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer. In: Cancer Journal from Scientific American. 1996 ; Vol. 2, No. 4. pp. 212-216.
@article{5f39f7421ecd4b01936ee703240182e6,
title = "Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer",
abstract = "PURPOSE: The bcl-2 gene belongs to a new category of oncogene that inhibits programmed cell death (apoptosis). No data are available on the frequency or clinical importance of its expression in patients with small cell lung cancer (SCLC), although its expression is reported in SCLC cell lines. We investigated the correlation between bcl-2 expression and prognosis, including response to chemotherapy, in SCLC patients and report our findings here. MATERIALS AND METHODS: Tumor specimens biopsied bronchoscopically in 38 SCLC patients were used for immunohistochemical study. Bcl-2 oncoprotein was detected by obtaining an immunostain using a specific monoclonal antibody, DAKO-bcl-2, 124. All patients received more than two courses of chemotherapy with 3- to 4-week intervals. RESULTS: We detected bcl-2 expression in 21 of the 38 SCLC patients (55{\%}). In 17 patients with bcl-2-negative tumors, the objective response to chemotherapy was 76{\%} with 12{\%} complete response and in 21 patients with bcl-2-positive tumors it was 62{\%} with 8{\%} complete response. The difference in response rate was not significant. In patients with bcl-2-positive tumors, survival time tended to be shorter than in those with bcl-2-negative tumors. There was no significant correlation between bcl-2 expression and clinical factors (gender, age, smoking, performance score, staging). CONCLUSIONS: In 21 of the 38 SCLC patients bcl-2 oncoprotein was abnormally expressed and its expression may be associated with shorter survival times and poor response to chemotherapy.",
author = "Koichi Takayama and Kenichi Ogata and Yoichi Nakanishi and Jun Yatsunami and Masayuki Kawasaki and Nobuyuki Hara",
year = "1996",
month = "12",
day = "1",
language = "English",
volume = "2",
pages = "212--216",
journal = "Cancer Journal from Scientific American",
issn = "1081-4442",
number = "4",

}

TY - JOUR

T1 - Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer

AU - Takayama, Koichi

AU - Ogata, Kenichi

AU - Nakanishi, Yoichi

AU - Yatsunami, Jun

AU - Kawasaki, Masayuki

AU - Hara, Nobuyuki

PY - 1996/12/1

Y1 - 1996/12/1

N2 - PURPOSE: The bcl-2 gene belongs to a new category of oncogene that inhibits programmed cell death (apoptosis). No data are available on the frequency or clinical importance of its expression in patients with small cell lung cancer (SCLC), although its expression is reported in SCLC cell lines. We investigated the correlation between bcl-2 expression and prognosis, including response to chemotherapy, in SCLC patients and report our findings here. MATERIALS AND METHODS: Tumor specimens biopsied bronchoscopically in 38 SCLC patients were used for immunohistochemical study. Bcl-2 oncoprotein was detected by obtaining an immunostain using a specific monoclonal antibody, DAKO-bcl-2, 124. All patients received more than two courses of chemotherapy with 3- to 4-week intervals. RESULTS: We detected bcl-2 expression in 21 of the 38 SCLC patients (55%). In 17 patients with bcl-2-negative tumors, the objective response to chemotherapy was 76% with 12% complete response and in 21 patients with bcl-2-positive tumors it was 62% with 8% complete response. The difference in response rate was not significant. In patients with bcl-2-positive tumors, survival time tended to be shorter than in those with bcl-2-negative tumors. There was no significant correlation between bcl-2 expression and clinical factors (gender, age, smoking, performance score, staging). CONCLUSIONS: In 21 of the 38 SCLC patients bcl-2 oncoprotein was abnormally expressed and its expression may be associated with shorter survival times and poor response to chemotherapy.

AB - PURPOSE: The bcl-2 gene belongs to a new category of oncogene that inhibits programmed cell death (apoptosis). No data are available on the frequency or clinical importance of its expression in patients with small cell lung cancer (SCLC), although its expression is reported in SCLC cell lines. We investigated the correlation between bcl-2 expression and prognosis, including response to chemotherapy, in SCLC patients and report our findings here. MATERIALS AND METHODS: Tumor specimens biopsied bronchoscopically in 38 SCLC patients were used for immunohistochemical study. Bcl-2 oncoprotein was detected by obtaining an immunostain using a specific monoclonal antibody, DAKO-bcl-2, 124. All patients received more than two courses of chemotherapy with 3- to 4-week intervals. RESULTS: We detected bcl-2 expression in 21 of the 38 SCLC patients (55%). In 17 patients with bcl-2-negative tumors, the objective response to chemotherapy was 76% with 12% complete response and in 21 patients with bcl-2-positive tumors it was 62% with 8% complete response. The difference in response rate was not significant. In patients with bcl-2-positive tumors, survival time tended to be shorter than in those with bcl-2-negative tumors. There was no significant correlation between bcl-2 expression and clinical factors (gender, age, smoking, performance score, staging). CONCLUSIONS: In 21 of the 38 SCLC patients bcl-2 oncoprotein was abnormally expressed and its expression may be associated with shorter survival times and poor response to chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0000305464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0000305464&partnerID=8YFLogxK

M3 - Article

C2 - 9166534

AN - SCOPUS:0000305464

VL - 2

SP - 212

EP - 216

JO - Cancer Journal from Scientific American

JF - Cancer Journal from Scientific American

SN - 1081-4442

IS - 4

ER -